AstraZeneca PLC (AZN)vsSionna Therapeutics, Inc. Common Stock (SION)
AZN
AstraZeneca PLC
$181.86
-0.54%
HEALTHCARE · Cap: $283.47B
SION
Sionna Therapeutics, Inc. Common Stock
$45.95
+3.89%
HEALTHCARE · Cap: $2.07B
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
SION
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.5%
Fair Value
$220.13
Current Price
$181.86
$38.27 discount
Intrinsic value data unavailable for SION.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SION
The strongest argument for SION centers on Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : SION
The primary concerns for SION are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while SION is a value play — different risk/reward profiles.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (62/100 vs 25/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sionna Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Sionna Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, particularly those characterized by protein misfolding and aggregation, including Alzheimer's and Parkinson's diseases. With a strong emphasis on proprietary technologies and a scientifically robust pipeline, Sionna is addressing critical unmet medical needs in this space. The company's strategic collaborations and commitment to research and development solidify its role as a significant contender in the biopharmaceutical sector, with a mission to enhance patient quality of life through groundbreaking advancements in neurology.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?